The value of the pharmaceuticals delivered in Romania in the first nine months of the year reached RON 7.3 billion at the distribution price, up 24.2 percent y-o-y, according to findings from the Pharma & Hospital Report released by Cegedim Romania. The growth rhythm has slowed down compared to the middle of the year following steps taken to reduce the public support for compensated medicines.
The total value of drugs released to patients in the third quarter of this year stood at RON 2.41 billion, up 20.4 percent compared to Q3 of the previous year. The growth is due mainly to the segment of drugs released on prescription, which had a value of RON 1.83 billion, up 23.8 percent. The OTC segment posted a value of RON 0.32 billion, up 15 percent, while the hospital segment stood at RON 0.26 billion, up 10.7 percent compared to the third quarter of 2009.
In between October 2009 and September 2010, the entire market stood at RON 9.52 billion, up 21.6 percent y-o-y. For the pharmaceuticals released on prescription segment the growth rate was of 27.4 percent, for the OTC segment the growth rate was of 10.7 percent, and 2.6 percent for the hospital segment.
The first place in the hierarchy of company sales on the local market is taken up by Sanofi-Aventis (including Zentiva and Sanofi-Pasteur) with 12-month sales standing at RON 891.4 million. Roche posted sales of RON 873.8 million, while Pfizer (including Wyeth) had sales of RON 636 million.
Novartis had sales of RON 583.9 million, GlaxoSmithKline of RON 581.3 million, Servier of RON 484.2 million, Merck&Co of RON 439.5 million, AstraZeneca of RON 366.2 million, Daiichi-Sankyo of RON 348.2 million, and Abbott of RON 266.6 million. The next ten position are taken up by Bayer, Antibiotice, Lilly, Menarini, Krka, Johnson & Johnson, Labormed, Richter Gedeon, Actavis, and Reckitt Benckiser.